Trial · NCT03192202
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 1 | G3/4 Infection and skin rash | 1 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 2 | G3/4 Infection and skin rash | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 3 | G3/4 Infection and skin rash | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 4 | G3/4 Infection and skin rash | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 1 | G1 IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 2 | G1 IRR | 2 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 3 | G1 IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 4 | G1 IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 1 | Death, G3 infection , IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 2 | Death, G3 infection , IRR | 1 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 3 | Death, G3 infection , IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 4 | Death, G3 infection , IRR | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 1 | No AE | 2 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 2 | No AE | 0 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 3 | No AE | 3 | Participants | |
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Cohort 4 | No AE | 6 | Participants | |
| Overall Response Rate (ORR) | Cohort 1 | 2 | Participants | ||
| Overall Response Rate (ORR) | Cohort 2 | 0 | Participants | ||
| Overall Response Rate (ORR) | Cohort 3 | 2 | Participants | ||
| Overall Response Rate (ORR) | Cohort 4 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03192202/results